Flexible dosing schemes for recombinant human erythropoietin - Lessons from our daily practice

Nephrology Dialysis Transplantation

Volumn 16, Issue SUPPL. 7, 2001, Pages 15-19

  Weiss, Lars ^a  

^a Centralsjukhuset   (Sweden)

Author keywords

Dosing frequency; Dosing requirements; Epoetin beta; Once weekly; rh Epo; Subcutaneous

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; EUROPE; HEMODIALYSIS PATIENT; HUMAN; INDIVIDUALIZATION; KIDNEY DISEASE; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT PLANNING; UNITED STATES;

EID: 0035172339     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.suppl_7.15     Document Type: Article

References (27)

1. Recombinant human erythropoietin: 10 years of clinical experience
2. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease
3. Recombinant human erythropoietin in anemia patients with end-stage renal disease
4. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients
5. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration
6. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.)
7. Intravenous vs subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD
8. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients: IV and SC erythropoietin
9. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis
10. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease
11. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients
12. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients
13. Differences in intravenous and subcutaneous application of recombinant human erythropoietin: A multicentre trial
14. Comparative crossover study of intravenously and subcutaneously administered recombinant human erythropoietin in hemodialysis patients
15. Erythropoietin response and route of administration
16. Must erythropoietin be injected by subcutaneous route for every hemodialyzed patient?
17. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: Comparison between intravenous and subcutaneous administration
18. European best practice guidelines for the management of anaemia in patients with chronic renal failure
19. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: Results from a randomized controlled multicentre trial
20. European Best Practice Guidelines 9-13: Anaemia management
21. Subcutaneous treatment with recombinant human erythropoietin: The influence of injection frequency and skin-fold thickness
22. What is the optimum frequency of administration of r-HuEpo for correcting anemia in hemodialysis patients?
23. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly
24. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients
25. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients
26. Individualizing target haemoglobin concentrations-tailoring treatment for renal anaemia